Retatrutide FDA Approval: Current Status and What to Expect
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated March 2026
Important: We are not doctors. Everything in this article is based on published research and publicly available clinical trial data. It is not medical advice. Talk to your physician before changing any medication or health protocol.
Key Takeaways
- Retatrutide is not FDA-approved as of March 2026. It is an investigational drug in Phase 3 clinical trials.
- Eli Lilly has 7 TRIUMPH Phase 3 trials underway. No NDA has been filed yet.
- Based on publicly available information, the most realistic NDA filing window is late 2026 to 2027.
- After NDA filing, standard FDA review takes 10-12 months. Priority Review, if granted, shortens that to 6-8 months.
- Using tirzepatide as a precedent: Phase 3 results in 2021 led to diabetes approval (Mounjaro) in May 2022 and obesity approval (Zepbound) in November 2023. A similar path for retatrutide would suggest earliest weight indication approval in 2027 or 2028.
- Prediction market signal: Polymarket gives FDA approval for retatrutide in 2026 only 18% odds (up 8% this month). Real money bets point to 2027 as the more likely timeline.
- Brand name has not been announced by Eli Lilly as of March 2026.
Current Status: Phase 3, No NDA Filed
Retatrutide has completed Phase 2 and is now in a large Phase 3 program called TRIUMPH. Phase 2 results showed up to 24.2% body weight loss at 48 weeks (PMID 37366315). The first Phase 3 readout (February 2026) showed 28.7% weight loss with substantial osteoarthritis pain relief. For a broader overview, see our retatrutide guide.
No New Drug Application (NDA) has been filed with the FDA. An NDA is the formal submission package that requests approval. You cannot file one until Phase 3 data is in hand and analyzed.
For the full trial-by-trial breakdown of all 7 TRIUMPH studies, see our retatrutide clinical trials tracker.
What Eli Lilly Needs to File an NDA
Before filing an NDA for retatrutide, Eli Lilly needs to accomplish several things.
Positive Phase 3 primary endpoint results. The primary endpoint for a weight management drug is typically mean percentage body weight reduction compared to placebo at a specified timepoint (often 68-72 weeks). The FDA generally expects at least 5% greater weight loss than placebo, and at least 35% of participants achieving 5% or more body weight reduction. For a drug to be competitive commercially, significantly larger effects are expected.
Safety data from large, diverse populations. Phase 3 trials enroll hundreds to thousands of participants. The FDA requires this scale to detect adverse events that occur in a small percentage of users but would affect large numbers of patients after approval. Dysesthesia, reported in Phase 2 at 8.8-20.9% of participants depending on dose, will be closely tracked. For the full breakdown of retatrutide's current safety profile from Phase 2 data, see our is retatrutide safe review.
Complete NDA package. This includes the full clinical trial dataset, preclinical data, chemistry and manufacturing data, proposed labeling, and risk evaluation and mitigation strategies if required. A complete NDA for a drug like this runs into the hundreds of thousands of pages of documentation.
Once filed, the FDA has 60 days to accept the application. Acceptance confirms it is complete enough to review. The review clock starts at that point.
FDA Review Timeline After NDA Filing
The standard FDA review pathway takes 10-12 months from acceptance of the NDA to a decision. This is called the standard review pathway.
The FDA also has a Priority Review designation, which shortens the timeline to 6-8 months. Priority Review is granted for drugs that offer "significant improvements in the safety or effectiveness of the treatment, prevention, or diagnosis of serious conditions." Given the magnitude of retatrutide's Phase 2 weight loss results, Priority Review would be a reasonable expectation, though not guaranteed.
There is also the Breakthrough Therapy designation, which Eli Lilly may have sought or could seek. Breakthrough Therapy provides more intensive FDA guidance during development and may expedite review, but it does not guarantee faster approval.
An advisory committee (AdCom) hearing is often part of the approval process for drugs in this category. The FDA convenes an independent panel of experts to review the data and make a non-binding recommendation. The FDA generally follows AdCom recommendations but is not required to do so. Tirzepatide's obesity approval did not require an AdCom meeting, but that may not hold for all future GLP-1 class drugs.
The Tirzepatide Precedent
Tirzepatide provides the most relevant precedent for estimating retatrutide's approval timeline. Both are Eli Lilly drugs in the same drug class, targeting overlapping receptor systems, for overlapping indications.
Here is the tirzepatide timeline:
- 2019-2021: SURPASS Phase 3 trials for type 2 diabetes
- May 2022: FDA approval for type 2 diabetes (Mounjaro)
- 2021-2022: SURMOUNT Phase 3 trials for obesity begin
- November 2023: FDA approval for chronic weight management in adults with obesity (Zepbound)
- June 2024: FDA approval for obstructive sleep apnea (additional indication)
From the first Phase 3 results to the diabetes approval was roughly one year. From the diabetes approval (May 2022) to the obesity approval (November 2023) took approximately 18 months, partly because obesity requires its own dedicated Phase 3 program with different primary endpoints than diabetes.
If retatrutide follows a similar path:
- Phase 3 data readouts for diabetes indication: potentially 2026
- NDA filing for diabetes: potentially late 2026
- Diabetes approval (best case): 2027
- Obesity-specific Phase 3 completion: 2026-2027
- NDA filing for obesity: 2027
- Obesity approval (best case): 2027-2028
These are reasonable estimates based on available public information. They are not guarantees, and Eli Lilly has not provided a specific public commitment to these dates as of March 2026.
Best Case vs. Realistic vs. Delayed Scenarios
Best case scenario: Phase 3 primary endpoints are met cleanly (the 28.7% weight loss and osteoarthritis data already exceed the bar). Safety data shows no new signals that require additional study. Eli Lilly files an NDA for the diabetes indication in late 2026. FDA grants Priority Review and there is no AdCom delay. Diabetes approval arrives mid-2027. Obesity filing follows quickly after. Obesity approval arrives late 2027 or early 2028. Multiple medical information sites now converge on this timeline. Polymarket, where bettors wager real money on outcomes, gives only 18% odds of FDA approval happening in 2026, reinforcing that 2027 is the consensus expectation.
Realistic scenario: Phase 3 results take until 2027 to fully compile. NDA filing happens in 2027. Standard 10-12 month review leads to approval in 2028, with the obesity indication following six to twelve months later.
Delayed scenario: Phase 3 produces unexpected safety findings that require additional trials or protocol amendments. The dysesthesia signal from Phase 2 requires characterization. The FDA requests a cardiovascular outcomes trial completion before granting obesity approval. Timeline slips to 2029 or beyond.
The delayed scenario is not the most probable outcome, but it is not negligible. Drug development is genuinely unpredictable. More than one drug with compelling Phase 2 data has encountered problems in Phase 3.
What the Brand Name Will Mean
Eli Lilly has not announced a brand name for retatrutide as of March 2026. The compound name "retatrutide" and its internal designation "LY3437943" are what appear in published research and clinical trial registrations.
When a brand name is announced, it will signal that Lilly is moving toward commercial launch. Brand name announcements typically happen in the 12-24 months before expected approval, as the company begins market preparation, training sales teams, negotiating formulary placement with payers, and building public awareness.
For context: Mounjaro and Zepbound are two different brand names for tirzepatide, each tied to a specific indication (diabetes and obesity respectively). It is possible retatrutide will follow a similar pattern, with different brand names for different indications.
The brand name also signals the beginning of the pricing and insurance coverage conversation. Tirzepatide launched at list prices around $1,000 per month for the obesity indication, with significant variation based on insurance coverage. Retatrutide pricing will reflect its clinical profile, competitive positioning against tirzepatide and future competitors, and Lilly's commercial strategy at the time of launch.
What This Means If You Are Waiting
Standard prescription access is at minimum 18-24 months away under the best case scenario, and more likely 2-3 years from today.
For a complete breakdown of current access options including clinical trial enrollment, research compounds, and what post-approval access will look like, see our guide to getting retatrutide in 2026.
Frequently Asked Questions {#faq}
Is retatrutide FDA-approved?
No. Retatrutide is not FDA-approved as of March 2026. It is an investigational drug in Phase 3 clinical trials. It is not legally available for prescription use outside of clinical trial participation.
When will retatrutide be approved?
Eli Lilly has not announced a specific approval target date. Based on Phase 3 trial timelines and the precedent set by tirzepatide, a realistic estimate is that a diabetes indication could be filed in late 2026 to 2027 and an obesity indication in 2027 to 2028. Approval in the 2027-2028 range is the best case scenario. Delays are possible.
What is the TRIUMPH trial program?
TRIUMPH is the name for Eli Lilly's Phase 3 clinical trial program for retatrutide. It consists of 7 separate trials evaluating retatrutide in different populations and for different endpoints, including obesity, type 2 diabetes, and cardiovascular outcomes. Results from these trials are required before an NDA can be filed.
How long does FDA review take after an NDA is filed?
Standard FDA review takes 10-12 months from acceptance of the NDA. Priority Review, which can be granted for drugs addressing serious conditions with significant improvement over available therapies, shortens that to 6-8 months. Both pathways are possible for retatrutide.
Can I access retatrutide now?
The only legal way to access retatrutide currently is through enrollment in an active TRIUMPH clinical trial. Eligibility requirements and enrollment status vary. ClinicalTrials.gov is the official source for current trial listings and recruitment status.
What do prediction markets say about retatrutide approval?
Polymarket, a platform where people bet real money on future outcomes, gives retatrutide FDA approval in 2026 only 18% odds as of March 2026. That number is up 8% from the prior month, suggesting growing optimism, but the market still strongly favors 2027 as the more likely approval year. Prediction markets are not guarantees, but they aggregate the collective judgment of people with financial skin in the game.
Will retatrutide be covered by insurance?
Insurance coverage cannot be predicted before approval. The precedent from tirzepatide suggests that coverage will vary significantly across payers and may be contested despite FDA approval. Many commercial plans and Medicare Part D have historically limited coverage for obesity medications. That policy landscape may shift by the time retatrutide is approved, but nothing is guaranteed.
Related Reading
- How Retatrutide Works: The Triple Agonist Mechanism Explained
- Retatrutide and Sleep Apnea: What the Weight Loss Data Tells Us
- CagriSema Weight Loss Results: What the Phase 3 Data Actually Shows
- GLP-1 Peptides: The Complete Guide
- Semaglutide vs. Liraglutide: How to Pick the Right GLP-1 for Your Situation
Medical Disclaimer
The information on this page is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Peptide Nerds is an editorial research site, not a medical practice. The editorial team consists of researchers and writers, not licensed medical professionals.
Timeline estimates in this article are based on publicly available information as of March 2026 and the precedent of similar drugs. Drug development timelines are inherently uncertain. Nothing on this page constitutes investment advice or a commitment by Eli Lilly or any other party.
Always seek the advice of your physician or a qualified health provider with any questions you have regarding a medical condition, treatment option, or medication change. Never disregard professional medical advice or delay seeking it because of something you have read on this website.
Sources
- Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial." NEJM 2023. (PMID 37366315)
- Rosenstock J, et al. Retatrutide Phase 1 Clinical Trial. Diabetes Care, 2023 — Early-phase retatrutide data
- FDA. "Novel Drug Approvals for 2022." U.S. Food and Drug Administration. Tirzepatide (Mounjaro) diabetes approval May 2022. fda.gov
- FDA. "Novel Drug Approvals for 2023." U.S. Food and Drug Administration. Tirzepatide (Zepbound) obesity approval November 2023. fda.gov
- FDA. "PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2023 Through 2027." Standard review 10-12 months, Priority Review 6-8 months. fda.gov
- Eli Lilly. "TRIUMPH Phase 3 Program Overview." ClinicalTrials.gov. Multiple trial registrations under "retatrutide." clinicaltrials.gov
- Polymarket. "FDA approves Retatrutide this year?" March 2026. - 18% Yes, 82% No as of March 2026
- Eli Lilly press release. "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs."
Schema Markup
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "Organization",
"@id": "https://peptidenerds.com/#organization",
"name": "Peptide Nerds",
"url": "https://peptidenerds.com",
"logo": {
"@type": "ImageObject",
"url": "https://peptidenerds.com/images/logo.png"
}
},
{
"@type": "Article",
"@id": "https://peptidenerds.com/blog/retatrutide-fda-approval-timeline#article",
"headline": "Retatrutide FDA Approval: Current Status and What to Expect",
"description": "Retatrutide is in Phase 3 trials. No NDA filed yet. Here's the realistic approval timeline, what Eli Lilly needs to file, and what tirzepatide's history tells us.",
"author": {
"@type": "Organization",
"name": "Peptide Nerds Editorial Team",
"@id": "https://peptidenerds.com/#organization"
},
"publisher": {
"@id": "https://peptidenerds.com/#organization"
},
"datePublished": "2026-03-13",
"dateModified": "2026-03-13",
"image": "https://peptidenerds.com/images/retatrutide-fda-approval-timeline.jpg",
"mainEntityOfPage": "https://peptidenerds.com/blog/retatrutide-fda-approval-timeline"
},
{
"@type": "FAQPage",
"@id": "https://peptidenerds.com/blog/retatrutide-fda-approval-timeline#faq",
"mainEntity": [
{
"@type": "Question",
"name": "Is retatrutide FDA-approved?",
"acceptedAnswer": {
"@type": "Answer",
"text": "No. Retatrutide is not FDA-approved as of March 2026. It is an investigational drug in Phase 3 clinical trials and is not legally available for prescription use outside of clinical trial participation."
}
},
{
"@type": "Question",
"name": "When will retatrutide be approved?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Eli Lilly has not announced a specific approval target date. Based on Phase 3 trial timelines and the precedent set by tirzepatide, a realistic estimate is a diabetes indication NDA filed in late 2026 to 2027 and an obesity indication in 2027 to 2028. Approval in the 2027-2028 range is the best case scenario."
}
},
{
"@type": "Question",
"name": "What is the TRIUMPH trial program?",
"acceptedAnswer": {
"@type": "Answer",
"text": "TRIUMPH is Eli Lilly's Phase 3 clinical trial program for retatrutide. It consists of 7 separate trials evaluating retatrutide in different populations and for different endpoints, including obesity, type 2 diabetes, and cardiovascular outcomes."
}
},
{
"@type": "Question",
"name": "How long does FDA review take after an NDA is filed?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Standard FDA review takes 10-12 months from acceptance of the NDA. Priority Review, which may be granted for drugs with significant improvements over available therapies, shortens that to 6-8 months."
}
},
{
"@type": "Question",
"name": "Can I access retatrutide now?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The only legal way to access retatrutide currently is through enrollment in an active TRIUMPH clinical trial. Eligibility requirements and enrollment status vary by trial. ClinicalTrials.gov is the official source for current listings."
}
},
{
"@type": "Question",
"name": "Will retatrutide be covered by insurance?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Insurance coverage cannot be predicted before approval. The precedent from tirzepatide suggests coverage will vary significantly across payers and may be contested despite FDA approval. The coverage landscape may shift by the time retatrutide is approved."
}
}
]
}
]
}
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.